νλλ‘μ½λ₯΄ν°μ μμΈν¬λ€μ΄νΈ
**νλλ‘μ½λ₯΄ν°μ μμΈν¬λ€μ΄νΈ**λ μμνμμ μ£Όλ‘ μΌμ¦μ± λ° μμμ± νΌλΆ μ§νκ³Ό κΈμ± λλ μ¬λ°μ± μΈμ΄μΌ μΉλ£μ μ¬μ©λλ κ°λ ₯ν κ΅μμ© **μ½λ₯΄ν°μ½μ€ν λ‘μ΄λ**μ λλ€. > **μμ ν:** λμμ€ν λ₯΄ μ ꡬμ½λ¬Ό(pro-drug)λ‘ μ μ‘°λμ΄ νΌλΆμμ λμ κ΅μ νμΌ ν¨κ³Όλ₯Ό μ 곡νλ λμμ, μ μ ν‘μ λ° κΈλ£¨μ½μ½λ₯΄ν°μ½μ΄λμ κ΄λ ¨λ μ νμ μΈ μ μ λΆμμ©(λΆμ μ΅μ λλ κ° ν¨μ μμΉ μμΉ λ±)μ ν¬κ² μ΅μνν©λλ€.
μμ© κΈ°μ : Hydrocortisone aceponate is a highly lipophilic **pro-drug**. Upon application, it penetrates the stratum corneum and is biotransformed by local esterases in the epidermis β **hydrocortisone 17-propionate** (the active form). It binds to local glucocorticoid receptors to inhibit inflammatory pathways, reducing erythema, pruritus, and swelling, while its rapid local metabolism minimizes systemic distribution.
λλ¬Ό μ’ λ³ μ©λ
- Pruritic inflammatory skin disease Β· 2 pumps of spray per 10 cm x 10 cm square of skin (delivers 1.52 ΞΌg/cm2) Β· topical Β· q24h Β· 7 days Β· Cortavance spray
- Otitis externa Β· 1 pump (1 ml) per ear Β· topical Β· q24h Β· 5 days Β· Easotic (combination product)
- General Β· Dose not established Β· topical Β· unknown Β· unknown Β· Safety and efficacy not fully established in cats.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Ulcerated skin
- Perforated tympanic membrane (ear drum)
- Cutaneous ulcers
- Known hypersensitivity to corticosteroids
- Concurrent systemic viral or fungal infections
- Use on large surface areas for prolonged periods without veterinary supervision
μ΄μλ°μ
- Epidermal atrophy (with protracted use)
- Aural erythema (otic preparation)
- Transient hearing loss in geriatric dogs (rare, otic preparation)
- Transient local erythema
- Skin thinning or atrophy (rare, usually only with prolonged use)
- Delayed wound healing
- Systemic glucocorticoid effects (extremely rare due to rapid metabolism)
μ½λ¬Ό μνΈμμ©
- Other topical corticosteroids Β· Increased risk of local skin atrophy and potential systemic absorption Β· moderate
λͺ¨λν°λ§
- Resolution of pruritus and inflammation
- Signs of epidermal atrophy (skin thinning) with prolonged use
- Liver enzyme activities (during long-term use)
- Cortisol response to ACTH stimulation (during long-term use)
- Resolution of pruritus and erythema
- Signs of local skin thinning or atrophy with prolonged use
κ³Όμ©λ
Massive over-application or protracted use can result in **epidermal atrophy** (thinning of the skin). While systemic effects (such as increases in liver enzyme activities or depression of cortisol response to ACTH stimulation) are minimized by the pro-drug formulation, they may theoretically occur with significant overdosage or ingestion.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.